Abstract: Living-related liver transplantation (LRLT) has become a standard treatment for end-stage liver disease, achieving survival rates of up to 80%. However, the postoperative period is a complex "physiological tightrope," where clinicians must balance aggressive immunosuppression against the risks of systemic infection and vascular failure. This paper reviews the management protocols for acute rejection, vascular thrombosis, and infectious complications, highlighting the role of multidisciplinary care and interventional radiology in ensuring graft survival.
Introduction
While LRLT offers a life-saving alternative to cadaveric transplantation, it introduces unique postoperative challenges. Recipients are often hemodynamically unstable due to massive fluid shifts and are highly susceptible to complications that can lead to rapid graft loss. The primary clinical focus is on managing three critical threats: acute cellular rejection, vascular catastrophes (such as hepatic artery thrombosis), and systemic infections, which remain the leading cause of mortality.
Clinical Management and Monitoring Protocols
The protocols established at Nippon Medical School and Jichi Medical School emphasize a multifaceted approach to postoperative care:
- Immunosuppression: A dual-drug regimen of Tacrolimus and Methylprednisolone is standard. Steroids are tapered using a "recycle method," with monoclonal antibodies (OKT3) reserved for steroid-resistant rejection.
- Hemodynamic Stability: Managing "third space" fluid shifts is vital, as patients can gain significant water weight during prolonged surgeries, impacting organ perfusion.
- Anticoagulation: To prevent thrombosis in small reconstructed vessels, low-molecular-weight heparin and Antithrombin III are used, requiring a delicate balance to avoid internal hemorrhage.
- Vigilant Monitoring: Daily (often twice-daily) color Doppler ultrasound is essential for the early detection of vascular complications.
Key Insights: The Postoperative Timeline
Complications in LRLT typically follow a predictable chronological pattern. Intraabdominal bleeding is most common within the first 48 hours, while vascular thrombosis usually occurs within the first two weeks. Viral infections, such as Cytomegalovirus (CMV), typically emerge after the first month of immunosuppression.
A significant challenge in LRLT is the "small-for-size syndrome." If the donor graft volume is less than 40% of the recipient's standard liver volume, the risk of intractable ascites and cholestasis increases. Furthermore, outflow obstruction due to hepatic vein stenosis can occur, leading to liver dysfunction. In such cases, interventional radiology—specifically percutaneous balloon dilatation (venoplasty)—is a highly effective treatment.
Results and Outcomes
- Survival Rates: Overall survival for LRLT has reached approximately 80%.
- Rejection: Despite advanced drug regimens, acute rejection affects roughly 36% of patients.
- Vascular Complications: Hepatic artery thrombosis (HAT) occurs in 1.3–12% of cases, often requiring emergency surgical intervention or retransplantation.
- Infection: Infection remains the most significant cause of morbidity and mortality, accounting for 30–60% of postoperative deaths.
Conclusion
The success of living-related liver transplantation depends on prompt diagnosis and the integration of specialized expertise from hepatologists, surgeons, and radiologists. While surgical techniques and immunosuppressive agents have advanced, the core challenge remains the management of the immunocompromised state and the prevention of vascular failure. Future research must focus on optimizing immunosuppression to minimize infectious risks without compromising graft acceptance.
Summary updated